Navigation Links
Common gene version optimizes thinking -- but with a possible downside

Most people inherit a version of a gene that optimizes their brain's thinking circuitry, yet also appears to increase risk for schizophrenia, a severe mental illness marked by impaired thinking, scientists at the National Institutes of Health's (NIH) National Institute of Mental Health (NIMH) have discovered. The seeming paradox emerged from the first study to explore the effects of variation in the human gene for a brain master switch, DARPP-32.

The researchers identified a common version of the gene and showed how it impacts the way two key brain regions exchange information, affecting a range of functions from general intelligence to attention.

Three fourths of subjects studied had at least one copy of the version that results in more efficient filtering of information processed by the brain's executive hub, the prefrontal cortex. However, the same version was also more prevalent among people who developed schizophrenia, a severe mental illness marked by delusions, hallucinations and impaired emotion that affects one percent of the population.

"We have found that DARPP-32 shapes and controls a circuit coursing between the human striatum and prefrontal cortex that affects key brain functions implicated in schizophrenia, such as motivation, working memory and reward related learning," explained Andreas Meyer-Lindenberg, M.D.

"Our results raise the question of whether a gene variant favored by evolution, that would normally confer advantage, may translate into a disadvantage if the prefrontal cortex is impaired, as in schizophrenia," added Daniel Weinberger, M.D. "Normally, enhanced cortex connectivity with the striatum would provide increased flexibility, working memory capacity and executive control. But if other genes and environmental events conspire to render the cortex incapable of handling such information, it could backfire -- resulting in the neural equivalent of a superhighway to a dead-end."

Meyer-Linden berg, Weinberger and colleagues in the NIMH Genes, Cognition and Psychosis program report their results in the February 9, 2007 issue of the Journal of Clinical Investigation.

Previous studies in animals over two decades, most notably by Nobel Laureate and NIMH grantee Paul Greengard, M.D., Rockefeller University, had established that DARPP-32 in the striatum switches streams of information from multiple brain chemical systems for processing by the cortex. Both the neurotransmitter that it works through, dopamine, and the chromosomal site of its gene have been implicated in schizophrenia.

"Although several groups have looked for possible clinical relevance of DARPP-32, they have not met with great success," noted Greengard. "This study shows a strong connection between this molecule and human cognition -- and perhaps with schizophrenia."

"These first glimpses of DARPP-32 at work in the living human brain build on a quarter century of investigations by Greengard's team that ultimately linked this pivotal protein to depression and substance abuse as well as to schizophrenia," added NIMH Director Thomas Insel, M.D.

To understand DARPP-32's role in the human brain, the NIMH researchers used genetic, structural and functional magnetic resonance imaging, and post-mortem techniques to identify the human gene's variants and their functional consequences. Seventy five percent of subjects had the most common version of the gene, which boosted circuit activation, structural and functional connectivity and performance on thinking tasks, likely by increasing gene expression. In 257 affected families, people with schizophrenia were more likely to have this common version of the DARPP-32 gene.
'"/>

Source:NIH/National Institute of Mental Health


Related biology news :

1. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
2. Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined
3. Men Estimate Mens Risks Of Common Disorders Higher Than Women Do, And Vice Versa
4. Use of Antibiotics for Acne May Increase Risk of Common Illness
5. Common viruses may cause cancer
6. Common alternative treatment for liver disease is found to be ineffective
7. Common molecular signature identified in solid tumors
8. Common bacteria pirate natural mechanism to get inside cells
9. Commonly used antidepressants may also affect human immune system
10. Common practices at petting zoos put visitors at risk
11. Common enzyme is a key player in DNA repair

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
(Date:11/19/2016)... Securus Technologies, a leading provider of civil and criminal ... monitoring, announced today that it has offered a challenge ... technology judge determine who has the largest and best ... platform, and the best customer service. "ICSolutions ... we do – which clearly is not the case ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... 5, 2016  Renova™ Therapeutics, a biotechnology company ... and other chronic diseases, announced that Catherine ... Chief Financial Officer (CFO), effective today. ... of experience in financial management for a variety ... companies. Most recently, Ms. Bovenizer was the Vice ...
(Date:12/5/2016)... YORK , December 5, 2016 ... player worldwide, with almost $108 billion of revenue and ... $170 billion were spent on global biopharmaceuticals, and this ... This morning, Stock-Callers.com has lined up these four equities ... ), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ), ...
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation ... and lumbar disc production, company President, Jake Lubinski will be traveling to Switzerland ... AxioMed disc in Bern, Lucerne, and Zurich to discuss the benefits of a ...
(Date:12/2/2016)... -- Research and Markets has announced the addition ... Companies" to their offering. ... , , ... industries is anticipated. Nanotechnology will be applied at all stages ... diagnostic applications in clinical trials. Many of the assays based ...
Breaking Biology Technology: